Pfenex

Pfenex wins $143.5M anthrax vaccine contract

Wednesday, August 19, 2015

Pfenex, a San Diego-based clinical-stage biologics company, has signed a five-year, cost plus fixed-fee contract valued at up to $143.5 million with the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), for the advanced development of Px563L, a mutant recombinant protective antigen anthrax vaccine.

[Read More]